{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T10:46:13Z","timestamp":1782729973687,"version":"3.54.5"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["23FC1015"],"award-info":[{"award-number":["23FC1015"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["23FC1027"],"award-info":[{"award-number":["23FC1027"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with inflammatory bowel disease (IBD) are at increased risk of acute pancreatitis (AP). However, the clinical characteristics of AP in IBD and the differences between ulcerative colitis (UC) and Crohn\u2019s disease (CD) remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a nationwide, multicenter, retrospective study at 28 institutions in Japan. Patients\u2009\u2265\u200916\u00a0years with UC or CD treated between 2012 and 2021 were included. We assessed the characteristics of AP in IBD, including differences between UC and CD. We also compared UC and CD patients with and without AP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 24,849 patients with IBD (16,233 UC and 8,616 CD), 342 (1.4%) developed AP. Among these AP cases, severe AP and mortality were observed in 7.6% and 0.6%, respectively. Drug-induced AP was the most common etiology (55.6%), and autoimmune pancreatitis (AIP) ranked third (10.8%). Compared with UC, CD patients with AP had higher rates of intensive care unit admission (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.002) and severe AP (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.003). CD (odds ratio, 2.96;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.02) and drug-induced or AIP etiology (odds ratio, 0.19;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001) were associated with severe AP. UC patients with AP had higher rates of pancolitis (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), extraintestinal manifestations (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.001), and steroid dependence (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.006) than those without AP.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>AP in IBD showed distinct clinical characteristics compared with AP in the general population. CD patients may develop more severe AP than UC, whereas UC patients with AP may have more aggressive and\/or refractory disease features compared with those without AP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00535-026-02476-4","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T09:02:29Z","timestamp":1782723749000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical characteristics of acute pancreatitis in patients with inflammatory bowel disease: a nationwide survey in Japan"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6214-7337","authenticated-orcid":false,"given":"Tetsuya","family":"Takikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Kakuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Kikuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serina","family":"Haruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami","family":"Kawamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Shinzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyoshi","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikihiro","family":"Fujiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuto","family":"Saiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanao","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakiko","family":"Hiraoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuya","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Narimatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shojiro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kagaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichiro","family":"Hagiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noritaka","family":"Takatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nakase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuichi","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoki","family":"Furuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsu","family":"Kinjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotake","family":"Sakuraba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Tashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Naganuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fukunori","family":"Kinjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohisa","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadakazu","family":"Hisamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Masamune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Japan Pancreatitis Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Hokari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Igawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Kurimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Maruo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Shirakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Takagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Umeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"2476_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0156-2","volume":"6","author":"G Roda","year":"2020","unstructured":"Roda G, Chien Ng S, Kotze PG, et al. Crohn\u2019s disease. Nat Rev Dis Primers. 2020;6:22.","journal-title":"Nat Rev Dis Primers"},{"key":"2476_CR2","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00535-021-01784-1","volume":"56","author":"H Nakase","year":"2020","unstructured":"Nakase H, Uchino M, Shinzaki S, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol. 2020;56:489\u2013526.","journal-title":"J Gastroenterol"},{"key":"2476_CR3","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","volume":"402","author":"C Le Berre","year":"2023","unstructured":"Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis. Lancet. 2023;402:571\u201384.","journal-title":"Lancet"},{"key":"2476_CR4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","volume":"142","author":"NA Molodecky","year":"2012","unstructured":"Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46\u201354.","journal-title":"Gastroenterology"},{"key":"2476_CR5","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390:2769\u201378.","journal-title":"Lancet"},{"key":"2476_CR6","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1007\/s00535-019-01603-8","volume":"54","author":"Y Murakami","year":"2014","unstructured":"Murakami Y, Nishiwaki Y, Oba MS, et al. Estimated prevalence of ulcerative colitis and Crohn\u2019s disease in Japan in 2014: an analysis of a nationwide survey. J Gastroenterol. 2014;54:1070\u20137.","journal-title":"J Gastroenterol"},{"key":"2476_CR7","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1007\/s00535-021-01829-5","volume":"56","author":"K Ando","year":"2021","unstructured":"Ando K, Fujiya M, Watanabe K, et al. A nationwide survey concerning the mortality and risk of progressing severity due to arterial and venous thromboembolism in inflammatory bowel disease in Japan. J Gastroenterol. 2021;56:1062\u201379.","journal-title":"J Gastroenterol"},{"key":"2476_CR8","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1159\/000529338","volume":"7","author":"R Moroi","year":"2023","unstructured":"Moroi R, Yano K, Tarasawa K, et al. The impact of concomitant ulcerative colitis on the clinical course in patients with primary sclerosing cholangitis: an investigation using a nationwide database in Japan. Inflamm Intest Dis. 2023;7:147\u201354.","journal-title":"Inflamm Intest Dis"},{"key":"2476_CR9","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1053\/j.gastro.2021.07.042","volume":"161","author":"G Rogler","year":"2021","unstructured":"Rogler G, Singh A, Kavanaugh A, et al. Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management. Gastroenterology. 2021;161:1118\u201332.","journal-title":"Gastroenterology"},{"key":"2476_CR10","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1056\/NEJMra1505202","volume":"375","author":"CE Forsmark","year":"2016","unstructured":"Forsmark CE, Vege SS, Wilcox CM. Acute pancreatitis. N Engl J Med. 2016;375:1972\u201381.","journal-title":"N Engl J Med"},{"key":"2476_CR11","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S0140-6736(20)31310-6","volume":"396","author":"L Boxhoorn","year":"2020","unstructured":"Boxhoorn L, Voermans RP, Bouwense SA, et al. Acute pancreatitis. Lancet. 2020;396:726\u201334.","journal-title":"Lancet"},{"key":"2476_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8070916","volume":"8","author":"T Iida","year":"2019","unstructured":"Iida T, Wagatsuma K, Hirayama D, et al. The etiology of pancreatic manifestations in patients with inflammatory bowel disease. J Clin Med. 2019;8:916.","journal-title":"J Clin Med"},{"key":"2476_CR13","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1097\/MPA.0000000000001650","volume":"49","author":"B T\u00e9l","year":"2020","unstructured":"T\u00e9l B, Stubnya B, Gede N, et al. Inflammatory bowel diseases elevate the risk of developing acute pancreatitis: A meta-analysis. Pancreas. 2020;49:1174\u201381.","journal-title":"Pancreas"},{"key":"2476_CR14","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1053\/j.gastro.2018.12.041","volume":"156","author":"PK Garg","year":"2019","unstructured":"Garg PK, Singh VP. Organ failure due to systemic injury in acute pancreatitis. Gastroenterology. 2019;156:2008\u201323.","journal-title":"Gastroenterology"},{"key":"2476_CR15","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1053\/j.gastro.2024.02.052","volume":"167","author":"G Trikudanathan","year":"2024","unstructured":"Trikudanathan G, Yazici C, Evans Phillips A, et al. Diagnosis and management of acute pancreatitis. Gastroenterology. 2024;167:673\u201388.","journal-title":"Gastroenterology"},{"key":"2476_CR16","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.pan.2020.02.007","volume":"20","author":"A Garcia Garcia de Paredes","year":"2020","unstructured":"Garcia Garcia de Paredes A, Rodriguez de Santiago E, Rodriguez-Escaja C, et al. Idiopathic acute pancreatitis in patients with inflammatory bowel disease: a multicenter cohort study. Pancreatology. 2020;20:331\u20137.","journal-title":"Pancreatology"},{"key":"2476_CR17","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1097\/01.MIB.0000186485.30623.ad","volume":"11","author":"P Moolsintong","year":"2005","unstructured":"Moolsintong P, Loftus EV Jr, Chari ST, et al. Acute pancreatitis in patients with Crohn\u2019s disease: clinical features and outcomes. Inflamm Bowel Dis. 2005;11:1080\u20134.","journal-title":"Inflamm Bowel Dis"},{"key":"2476_CR18","doi-asserted-by":"publisher","first-page":"357","DOI":"10.5009\/gnl210241","volume":"16","author":"Y Zen","year":"2021","unstructured":"Zen Y. Type 2 autoimmune pancreatitis: consensus and controversies. Gut Liver. 2021;16:357\u201365.","journal-title":"Gut Liver"},{"key":"2476_CR19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/ecco-jcc\/jjv188","volume":"10","author":"N Teich","year":"2016","unstructured":"Teich N, Mohl W, Bokemeyer B, et al. Azathioprine-induced acute pancreatitis in patients with inflammatory bowel diseases\u2013a prospective study on incidence and severity. J Crohns Colitis. 2016;10:61\u20138.","journal-title":"J Crohns Colitis"},{"key":"2476_CR20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/jgh3.12849","volume":"7","author":"R Moroi","year":"2023","unstructured":"Moroi R, Tarasawa K, Ikeda M, et al. Severity of acute pancreatitis in patients with inflammatory bowel disease in the era of biologics: a propensity-score-matched analysis using a nationwide database in Japan. JGH Open. 2023;7:40\u20137.","journal-title":"JGH Open"},{"key":"2476_CR21","unstructured":"Ministry of Health, Labour and Welfare, Grant-in-Aid for Scientific Research on Intractable Diseases, \u201cResearch on Intractable Inflammatory Bowel Disorders\u201d (Hisamatsu Group), 2024, Diagnostic Criteria and Treatment Guidelines for Ulcerative Colitis and Crohn\u2019s Disease (revised version). http:\/\/www.ibdjapan.org\/. Accessed 24 Aug 2025."},{"key":"2476_CR22","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1002\/jhbp.1146","volume":"29","author":"T Takada","year":"2021","unstructured":"Takada T, Isaji S, Mayumi T, et al. JPN clinical practice guidelines 2021 with easy-to-understand explanations for the management of acute pancreatitis. J Hepatobiliary Pancreat Sci. 2021;29:1057\u201383.","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"27","key":"2476_CR23","first-page":"17","volume":"2012","author":"The Japan Pancreas Society, The Ministry of Health and Welfare Investigation Research Team for Intractable Pancreatic Disease. Clinical diagnostic criteria for Autoimmune Pancreatitis","year":"2011","unstructured":"The Japan Pancreas Society, The Ministry of Health and Welfare Investigation Research Team for Intractable Pancreatic Disease. Clinical diagnostic criteria for Autoimmune Pancreatitis. Article in Japanese with English abstract. J Jpn Pancreas (Suizo). 2011;2012(27):17\u201325.","journal-title":"J Jpn Pancreas (Suizo)"},{"key":"2476_CR24","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1097\/MPA.0000000000001443","volume":"49","author":"S Kawa","year":"2020","unstructured":"Kawa S, Kamisawa T, Notohara K, et al. Japanese Clinical Diagnostic Criteria for Autoimmune Pancreatitis, 2018: Revision of Japanese Clinical Diagnostic Criteria for Autoimmune Pancreatitis, 2011. Pancreas. 2020;49:e13\u20134.","journal-title":"Pancreas"},{"key":"2476_CR25","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/MPA.0b013e3182142fd2","volume":"40","author":"T Shimosegawa","year":"2011","unstructured":"Shimosegawa T, Chari ST, Frulloni L, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas. 2011;40:352\u20138.","journal-title":"Pancreas"},{"key":"2476_CR26","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/00004836-199312000-00004","volume":"17","author":"P Weber","year":"1993","unstructured":"Weber P, Seibold F, Jenss H. Acute pancreatitis in Crohn\u2019s disease. J Clin Gastroenterol. 1993;17:286\u201391.","journal-title":"J Clin Gastroenterol"},{"key":"2476_CR27","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/jgh.13171","volume":"31","author":"YT Chen","year":"2016","unstructured":"Chen YT, Su JS, Tseng CW, et al. Inflammatory bowel disease on the risk of acute pancreatitis: a population-based cohort study. J Gastroenterol Hepatol. 2016;31:782\u20137.","journal-title":"J Gastroenterol Hepatol"},{"key":"2476_CR28","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/1219464","author":"DB Kim","year":"2017","unstructured":"Kim DB, Chung WC, Lee JM, et al. Analysis of factors associated with the severity of acute pancreatitis according to etiology. Gastroenterol Res Pract. 2017. https:\/\/doi.org\/10.1155\/2017\/1219464.","journal-title":"Gastroenterol Res Pract"},{"key":"2476_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0200363","volume":"13","author":"BR Yang","year":"2018","unstructured":"Yang BR, Choi NK, Kim MS, et al. Prevalence of extraintestinal manifestations in Korean inflammatory bowel disease patients. PLoS ONE. 2018;13:e0200363.","journal-title":"PLoS ONE"},{"key":"2476_CR30","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000628","volume":"14","author":"KY Zhang","year":"2023","unstructured":"Zhang KY, Siddiqi I, Saad M, et al. Temporal analysis of inflammatory bowel disease and pancreatitis co-occurrence in children and adults in the United States. Clin Transl Gastroenterol. 2023;14:e00628.","journal-title":"Clin Transl Gastroenterol"},{"key":"2476_CR31","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/BF02391016","volume":"3","author":"M Yamamoto","year":"1996","unstructured":"Yamamoto M, Saitoh Y. Severe acute pancreatitis in Japan. J Hepatobiliary Pancreat Surg. 1996;3:203\u20139.","journal-title":"J Hepatobiliary Pancreat Surg"},{"key":"2476_CR32","unstructured":"Tamakoshi A, Hayashi O, Ohno Y, et al. Nationwide epidemiological survey of acute pancreatitis; 1999 Report of the Research Committee of Intractable Pancreatic Diseases, under the support of the Ministry of Health, Labour, and Welfare of Japan. Kumamoto Igakkai Zasshi. 2000; 36\u201341. (in Japanese)"},{"key":"2476_CR33","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.3748\/wjg.v12.i21.3314","volume":"12","author":"M Otsuki","year":"2006","unstructured":"Otsuki M, Hirota M, Arata S, et al. Consensus of primary care in acute pancreatitis in Japan. World J Gastroenterol. 2006;12:3314\u201323.","journal-title":"World J Gastroenterol"},{"key":"2476_CR34","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/MPA.0b013e318214812b","volume":"40","author":"K Satoh","year":"2011","unstructured":"Satoh K, Shimosegawa T, Masamune A, et al. Nationwide epidemiological survey of acute pancreatitis in Japan. Pancreas. 2011;40:503\u20137.","journal-title":"Pancreas"},{"key":"2476_CR35","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1097\/MPA.0000000000000200","volume":"43","author":"S Hamada","year":"2014","unstructured":"Hamada S, Masamune A, Kikuta K, et al. Nationwide epidemiological survey of acute pancreatitis in Japan. Pancreas. 2014;43:1244\u20138.","journal-title":"Pancreas"},{"key":"2476_CR36","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.pan.2020.04.013","volume":"20","author":"A Masamune","year":"2020","unstructured":"Masamune A, Kikuta K, Hamada S, et al. Clinical practice of acute pancreatitis in Japan: An analysis of nationwide epidemiological survey in 2016. Pancreatology. 2020;20:629\u201336.","journal-title":"Pancreatology"},{"key":"2476_CR37","unstructured":"Tanaka Y, Masamune A, Matsumoto R, et al. Nationwide epidemiological survey of acute pancreatitis in Japan, 2021: the impact of the COVID-19 pandemic and revised clinical guidelines. J Gastroenterol. 2025; epub ahead of print."},{"key":"2476_CR38","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.pan.2023.06.003","volume":"23","author":"AA Lee","year":"2023","unstructured":"Lee AA, Gupta S, Labban M, et al. Drug-induced acute pancreatitis due to medications used for inflammatory bowel disease: a VigiBase pharmacovigilance database study. Pancreatology. 2023;23:569\u201373.","journal-title":"Pancreatology"},{"key":"2476_CR39","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00535-022-01857-9","volume":"57","author":"K Okazaki","year":"2022","unstructured":"Okazaki K, Kawa S, Kamisawa T, et al. Amendment of the Japanese consensus guidelines for autoimmune pancreatitis, 2020. J Gastroenterol. 2022;57:225\u201345.","journal-title":"J Gastroenterol"},{"key":"2476_CR40","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.pan.2024.01.008","volume":"24","author":"T Takikawa","year":"2024","unstructured":"Takikawa T, Kikuta K, Sano T, et al. Maintenance steroid therapy is associated with decreased risk of malignancy and better prognosis of patients with autoimmune pancreatitis: a multicenter cohort study in Japan. Pancreatology. 2024;24:335\u201342.","journal-title":"Pancreatology"},{"key":"2476_CR41","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.pan.2024.11.018","volume":"25","author":"T Sano","year":"2025","unstructured":"Sano T, Kikuta K, Takikawa T, et al. Serum IgG4-negative and IgG4-positive type 1 autoimmune pancreatitis present with different clinicopathological features: An analysis of a nationwide survey in Japan. Pancreatology. 2025;25:82\u20138.","journal-title":"Pancreatology"},{"key":"2476_CR42","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s00535-019-01658-7","volume":"55","author":"A Masamune","year":"2020","unstructured":"Masamune A, Kikuta K, Hamada S, et al. Nationwide epidemiological survey of autoimmune pancreatitis in Japan in 2016. J Gastroenterol. 2020;55:462\u201370.","journal-title":"J Gastroenterol"},{"key":"2476_CR43","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/flgastro-2020-101405","volume":"12","author":"M Gordon","year":"2021","unstructured":"Gordon M, Grafton-Clarke C, Akobeng A, et al. Pancreatitis associated with azathioprine and 6-mercaptopurine use in Crohn\u2019s disease: a systematic review. Frontline Gastroenterol. 2021;12:423\u201336.","journal-title":"Frontline Gastroenterol"},{"key":"2476_CR44","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/j.1365-2036.2008.03746.x","volume":"28","author":"F Bermejo","year":"2008","unstructured":"Bermejo F, Lopez-Sanroman A, Taxonera C, et al. Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis. Aliment Pharmacol Ther. 2008;28:623\u20138.","journal-title":"Aliment Pharmacol Ther"},{"key":"2476_CR45","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1136\/gutjnl-2015-309275","volume":"65","author":"PA Hart","year":"2016","unstructured":"Hart PA, Levy MJ, Smyrk TC, et al. Clinical profiles and outcomes in idiopathic duct-centric chronic pancreatitis (type 2 autoimmune pancreatitis): the Mayo Clinic experience. Gut. 2016;65:1702\u20139.","journal-title":"Gut"},{"key":"2476_CR46","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/1751-2980.12286","volume":"16","author":"FM Zhang","year":"2015","unstructured":"Zhang FM, Xu CF, Shan GD, et al. Is gallstone disease associated with inflammatory bowel diseases? A meta-analysis. J Dig Dis. 2015;16:634\u201341.","journal-title":"J Dig Dis"},{"key":"2476_CR47","first-page":"136","volume":"16","author":"S Jasdanwala","year":"2015","unstructured":"Jasdanwala S, Babyatsky M. Crohn\u2019s disease and acute pancreatitis. A review of literature JOP. 2015;16:136\u201342.","journal-title":"A review of literature JOP"},{"key":"2476_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13133919","volume":"13","author":"G Catassi","year":"2024","unstructured":"Catassi G, Marmo C, Gasbarrini A, et al. Role of device-assisted enteroscopy in Crohn\u2019s disease. J Clin Med. 2024;13:3919.","journal-title":"J Clin Med"},{"key":"2476_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.703310","volume":"9","author":"R Linares","year":"2021","unstructured":"Linares R, Franc\u00e9s R, Guti\u00e9rrez A, et al. Bacterial translocation as inflammatory driver in Crohn\u2019s disease. Front Cell Dev Biol. 2021;9:703310.","journal-title":"Front Cell Dev Biol"},{"key":"2476_CR50","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1080\/1040841X.2019.1621795","volume":"45","author":"J Liu","year":"2019","unstructured":"Liu J, Huang L, Luo M, et al. Bacterial translocation in acute pancreatitis. Crit Rev Microbiol. 2019;45:539\u201347.","journal-title":"Crit Rev Microbiol"},{"key":"2476_CR51","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.3748\/wjg.v23.i19.3505","volume":"23","author":"JW Kim","year":"2017","unstructured":"Kim JW, Hwang SW, Park SH, et al. Clinical course of ulcerative colitis patients who develop acute pancreatitis. World J Gastroenterol. 2017;23:3505\u201312.","journal-title":"World J Gastroenterol"},{"key":"2476_CR52","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1097\/MIB.0000000000000392","volume":"21","author":"SR Vavricka","year":"2015","unstructured":"Vavricka SR, Schoepfer A, Scharl M, et al. Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2015;21:1982\u201392.","journal-title":"Inflamm Bowel Dis"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02476-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-026-02476-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02476-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T10:02:22Z","timestamp":1782727342000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-026-02476-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":52,"alternative-id":["2476"],"URL":"https:\/\/doi.org\/10.1007\/s00535-026-02476-4","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"26 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Shinichiro Shinzaki received research grants from AbbVie, JIMRO, Nippon Kayaku, Zeria Pharmaceutical, EA Pharma, Kyorin Pharmaceutical, and Mochida Pharmaceutical, serves as a consultant to AbbVie, Celltrion Healthcare, Eli Lilly, Janssen Pharmaceutical, Sekisui Medical, Bristol Myers Squibb, EA Pharma, Gilead Sciences, Kissei Pharmaceutical, and Takeda Pharmaceutical, and received lecture fees from AbbVie, Celltrion Healthcare, EA Pharma, Gilead Sciences, Janssen Pharmaceutical, JIMRO, Kissei Pharmaceutical, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Nippon Kayaku, Pfizer, and Sekisui Medical; Katsuyoshi Matsuoka received research grants from EA Pharma, Mochida Pharmaceutical, and AbbVie, serves as a consultant to Eli Lilly, Takeda Pharmaceutical, Pfizer, and MSD, received lecture fees from Mitsubishi Tanabe Pharma, Takeda Pharmaceutical, Janssen Pharmaceutical, AbbVie, EA Pharma, Pfizer, Mochida Pharmaceutical, Kyorin Pharmaceutical, Zeria Pharmaceutical, Kissei Pharmaceutical, Gilead Sciences, Celltrion Healthcare, Eli Lilly, and GlaxoSmithKline; Mikihiro Fujiya received research grants from EA Pharma, AYUMI Pharmaceutical, AbbVie, Otsuka Pharmaceutical, Zeria Pharmaceutical, Nippon Kayaku, Nobelpharma, Pfizer, Janssen Pharmaceutical, Kyorin Pharmaceutical, Mochida Pharmaceutical, Daiichi Sankyo, Mitsubishi Tanabe Pharma, and Takeda Pharmaceutical, received lecture fees from EA Pharma, AYUMI Pharmaceutical, AbbVie, Otsuka Pharmaceutical, Zeria Pharmaceutical, JIMRO, Nippon Kayaku, Nobelpharma, Pfizer, Janssen Pharmaceutical, Kyorin Pharmaceutical, Mochida Pharmaceutical, Daiichi Sankyo, and Mitsubishi Tanabe Pharma, and owns stock in Kamui Pharma; Sakiko Hiraoka received lecture fees from AbbVie, EA Pharma, Kyorin Pharmaceutical, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, and Janssen Pharmaceutical; Takayuki Matsumoto received lecture fees from Janssen Pharmaceutical and Gilead Sciences; Shin-ichiro Hagiwara received lecture fees from AbbVie, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical, and Alfresa Pharma; Hirotake Sakuraba received research grants from Yakult Honsha and AbbVie, and received lecture fees from AbbVie, Takeda Pharmaceutical, Janssen Pharmaceutical, Mitsubishi Tanabe Pharma, and EA Pharma; Makoto Naganuma received research grants from AbbVie and Mochida Pharmaceutical, and received lecture fees from EA Pharma, Gilead Sciences, Takeda Pharmaceutical, AbbVie, Janssen Pharmaceutical, Mitsubishi Tanabe Pharma, JIMRO, Kyorin Pharmaceutical, Mochida Pharmaceutical, and Pfizer; Tomohisa Takagi received research grants from PreMedica, Mitsubishi Tanabe Pharma, and AMED, and received lecture fees from Janssen Pharmaceutical, Mitsubishi Tanabe Pharma, Towa Pharmaceutical, Mochida Pharmaceutical, Takeda Pharmaceutical, AbbVie, EA Pharma, and Pfizer; Tadakazu Hisamatsu received research grants from Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, EA Pharma, AbbVie, JIMRO, Zeria Pharmaceutical, Kyorin Pharmaceutical, Nippon Kayaku, Pfizer, Boston Scientific, and Mochida Pharmaceutical, serves as a consultant to EA Pharma, AbbVie, Janssen Pharmaceutical, Pfizer, Mitsubishi Tanabe Pharma, JIMRO, Mochida Pharmaceutical, Bristol Myers Squibb, Eli Lilly, Gilead Sciences, and Abivax, and received lecture fees from EA Pharma, AbbVie, Janssen Pharmaceutical, Pfizer, Mitsubishi Tanabe Pharma, JIMRO, Mochida Pharmaceutical, Bristol Myers Squibb, Eli Lilly, and Gilead Sciences.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}